Associations Between Gut Microbiota and Diabetic Nephropathy: A Mendelian Randomization Study

Overview

Journal Aging Med (Milton)

Specialty Geriatrics

Date 2025 Feb 19

PMID 39968006

Authors

Yujun Xiong

Xingyun Zhu

Huazhao Xu

Zitian Zheng

Qingfeng Luo

Affiliations

Soon will be listed here.

Abstract

Objectives: Diabetic nephropathy (DN) is a severe complication of diabetes mellitus, and its pathogenesis remains incompletely understood. Emerging evidence suggests a potential link between gut microbiota and DN. This study aimed to explore the causal relationship between gut microbiota and DN using a two-sample Mendelian randomization (MR) approach.

Methods: Gut microbiota data were obtained from the MiBioGen consortium, which provides the most comprehensive genome-wide association studies (GWAS) on gut microbiota. Summary-level genetic data for DN were sourced from publicly available GWAS data provided by the FinnGen consortium. The primary analysis was conducted using the inverse variance-weighted (IVW) method, complemented by sensitivity analyses to evaluate pleiotropy and heterogeneity.

Results: Fourteen gut microbiota species demonstrated significant genetic associations with DN in the MR analysis, including five negatively and nine positively associated species, as determined by the IVW method. No evidence of pleiotropy or heterogeneity was observed, ensuring the robustness of the findings.

Conclusions: This study provides novel insight into the causal role of gut microbiota in DN pathogenesis, uncovering specific microbial species that may contribute to disease progression. These findings offer a promising avenue for future research and therapeutic development targeting gut microbiota.

References

Chen X, Dai W, Li H, Yan Z, Liu Z, He L . Targeted drug delivery strategy: a bridge to the therapy of diabetic kidney disease. Drug Deliv. 2022; 30(1):2160518. PMC: 9809356. DOI: 10.1080/10717544.2022.2160518. View

Davies N, Holmes M, Davey Smith G . Reading Mendelian randomisation studies: a guide, glossary, and checklist for clinicians. BMJ. 2018; 362:k601. PMC: 6041728. DOI: 10.1136/bmj.k601. View

Mosterd C, Kanbay M, van den Born B, van Raalte D, Rampanelli E . Intestinal microbiota and diabetic kidney diseases: the Role of microbiota and derived metabolites inmodulation of renal inflammation and disease progression. Best Pract Res Clin Endocrinol Metab. 2021; 35(3):101484. DOI: 10.1016/j.beem.2021.101484. View

Zhang L, Lu Q, Wu H, Cheng Y, Kang J, Xu Z . The Intestinal Microbiota Composition in Early and Late Stages of Diabetic Kidney Disease. Microbiol Spectr. 2023; 11(4):e0038223. PMC: 10434009. DOI: 10.1128/spectrum.00382-23. View

Lu X, Ma J, Li R . Alterations of gut microbiota in biopsy-proven diabetic nephropathy and a long history of diabetes without kidney damage. Sci Rep. 2023; 13(1):12150. PMC: 10374570. DOI: 10.1038/s41598-023-39444-4. View

Meijers B, Evenepoel P, Anders H . Intestinal microbiome and fitness in kidney disease. Nat Rev Nephrol. 2019; 15(9):531-545. DOI: 10.1038/s41581-019-0172-1. View

Dellamea B, Leitao C, Friedman R, Canani L . Nitric oxide system and diabetic nephropathy. Diabetol Metab Syndr. 2014; 6(1):17. PMC: 3928920. DOI: 10.1186/1758-5996-6-17. View

Burgess S, Davies N, Thompson S . Bias due to participant overlap in two-sample Mendelian randomization. Genet Epidemiol. 2016; 40(7):597-608. PMC: 5082560. DOI: 10.1002/gepi.21998. View

Natividad J, Verdu E . Modulation of intestinal barrier by intestinal microbiota: pathological and therapeutic implications. Pharmacol Res. 2012; 69(1):42-51. DOI: 10.1016/j.phrs.2012.10.007. View

10.

Qin J, Li Y, Cai Z, Li S, Zhu J, Zhang F . A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature. 2012; 490(7418):55-60. DOI: 10.1038/nature11450. View

11.

DeFronzo R, Reeves W, Awad A . Pathophysiology of diabetic kidney disease: impact of SGLT2 inhibitors. Nat Rev Nephrol. 2021; 17(5):319-334. DOI: 10.1038/s41581-021-00393-8. View

12.

Zhao H, Yang C, Liu T, Zhang M, Niu Y, Wang M . The roles of gut microbiota and its metabolites in diabetic nephropathy. Front Microbiol. 2023; 14:1207132. PMC: 10413983. DOI: 10.3389/fmicb.2023.1207132. View

13.

Mahmoodpoor F, Rahbar Saadat Y, Barzegari A, Ardalan M, Zununi Vahed S . The impact of gut microbiota on kidney function and pathogenesis. Biomed Pharmacother. 2017; 93:412-419. DOI: 10.1016/j.biopha.2017.06.066. View

14.

Wu R, Ruan X, Ruan D, Zhang J, Wang H, Zeng Q . Differences in gut microbiota structure in patients with stages 4-5 chronic kidney disease. Am J Transl Res. 2021; 13(9):10056-10074. PMC: 8507064. View

15.

Liu L, Zhang J, Cheng Y, Zhu M, Xiao Z, Ruan G . Gut microbiota: A new target for T2DM prevention and treatment. Front Endocrinol (Lausanne). 2022; 13:958218. PMC: 9402911. DOI: 10.3389/fendo.2022.958218. View

16.

Lan T, Tang T, Li Y, Duan Y, Yuan Q, Liu W . FTZ polysaccharides ameliorate kidney injury in diabetic mice by regulating gut-kidney axis. Phytomedicine. 2023; 118:154935. DOI: 10.1016/j.phymed.2023.154935. View

17.

Kurilshikov A, Medina-Gomez C, Bacigalupe R, Radjabzadeh D, Wang J, Demirkan A . Large-scale association analyses identify host factors influencing human gut microbiome composition. Nat Genet. 2021; 53(2):156-165. PMC: 8515199. DOI: 10.1038/s41588-020-00763-1. View

18.

Reynolds C, Del Greco M F, Allen R, Flores C, Gisli Jenkins R, Maher T . The causal relationship between gastro-oesophageal reflux disease and idiopathic pulmonary fibrosis: a bidirectional two-sample Mendelian randomisation study. Eur Respir J. 2023; 61(5). PMC: 10209472. DOI: 10.1183/13993003.01585-2022. View

19.

Inoue K, Ishibe S . Podocyte endocytosis in the regulation of the glomerular filtration barrier. Am J Physiol Renal Physiol. 2015; 309(5):F398-405. PMC: 4556893. DOI: 10.1152/ajprenal.00136.2015. View

20.

Tian E, Wang F, Zhao L, Sun Y, Yang J . The pathogenic role of intestinal flora metabolites in diabetic nephropathy. Front Physiol. 2023; 14:1231621. PMC: 10352811. DOI: 10.3389/fphys.2023.1231621. View